RxDoctor Payments Data

Michele Burns, PA

Physician Assistant · Santa Ana, CANPI 1437248572

Payments from drug & device makers

$2,700in general payments, 2019–2025

Across 108 payments — averaging $25.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$292
  • Neurocrine Biosciences, Inc.$269
  • Corcept Therapeutics$261
  • Acadia Pharmaceuticals Inc$224
  • Lilly USA, LLC$199
  • Teva Pharmaceuticals USA, Inc.$179
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$2,700100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,700 in reported general payments places this provider in the 85th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$264,183
Medicare patients
449
Services billed
3,668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban164$99,625
OzempicSemaglutide47$52,280
FarxigaDapagliflozin Propanediol83$39,119
JardianceEmpagliflozin42$30,582
JanuviaSitagliptin Phosphate22$24,480
XareltoRivaroxaban39$20,962
EntrestoSacubitril/Valsartan24$14,845
Breo ElliptaFluticasone/Vilanterol20$14,244
TradjentaLinagliptin43$12,741
TrulicityDulaglutide15$12,119
MyrbetriqMirabegron29$8,928
Mirtazapine349$7,809
NamzaricMemantine Hcl/Donepezil Hcl14$7,729
Memantine Hcl213$7,640
Levothyroxine Sodium527$6,199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$94$52,28047 claims
AstraZenecaFarxiga, Brilinta$16$44,77097 claims
MerckJanuvia$39$24,48022 claims
Johnson & JohnsonXarelto$16$20,96239 claims
NovartisEntresto$50$14,84524 claims
Lilly USA, LLCTrulicity$199$12,11915 claims
Astellas Pharma US IncMyrbetriq$93$8,92829 claims
AbbVieNamzaric$48$7,72914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →